Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Sadeleştirilmiş öğe sayfası
dc.contributor.authorBasaran, Gul
dc.contributor.authorDemirci, Umut
dc.contributor.authorYildiz, Fatih
dc.contributor.authorCicin, Irfan
dc.contributor.authorAktas, Burak Yasin
dc.contributor.authorOzturk, Banu
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorOyan, Basak
dc.contributor.authorSonmez, Ozlem
dc.contributor.authorEralp, Yesim
dc.contributor.authorGokmen, Erhan
dc.contributor.authorGunduz, Seyda
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorKeskin, Serkan
dc.date.accessioned2025-10-16T15:21:28Z
dc.date.issued2020
dc.description.abstractAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, MAY 29-31, 2020
dc.identifier.otherWOS:000560368304194
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7677
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleRetrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS